Tag Archives: Tailored Covalency®

Sanofi’s Rilzabrutinib Granted Fourth Orphan Drug Designation, Now Targeting Sickle Cell Disease

(IN BRIEF) Rilzabrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, has received orphan drug designation from the U.S. FDA for sickle cell disease. This marks the fourth such designation for the drug, which has already been recognized for its potential … Read the full press release

Sanofi to provide an update on its Immunology strategy at its Immunology Investor Event

(PRESS RELEASE) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced that the company will provide an update on its Immunology strategy at its Immunology Investor Event, which is taking place … Read the full press release

Sanofi tender offer for Principia Biopharma outstanding shares, August 28 – September 25, 2020

(PRESS RELEASE) PARIS, 28-Aug-2020 — /EuropaWire/ — French multinational pharmaceutical company Sanofi announces its intention to commence a tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of Principia Biopharma Inc. for $100 per share … Read the full press release